Form 4: Kiniksa Pharmaceuticals CFO Mark Ragosa Reports Stock Transactions

Mark Ragosa, CFO of Kiniksa Pharmaceuticals International, plc, reports the vesting and subsequent disposal of Class A Ordinary Shares to cover tax obligations.

Summary

• On April 26, 2025, Mark Ragosa, the Chief Financial Officer of Kiniksa Pharmaceuticals International, plc, reported transactions involving Class A Ordinary Shares.
• Specifically, 990 shares were acquired through the vesting of Restricted Share Units (RSUs).
• Simultaneously, 479 shares were disposed of at a price of $21.365 per share to satisfy tax withholding obligations related to the RSU vesting.
• Following these transactions, Ragosa directly owns 27,009 Class A Ordinary Shares.
• The RSUs vest over a four-year period, with 25% vesting annually from April 26, 2021.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock transactions by a company executive. The vesting of RSUs is generally a positive sign, but the sale of shares to cover taxes is a normal occurrence.

Positives

• The vesting of RSUs indicates a form of compensation and alignment of the CFO's interests with the company's performance.

Negatives

• The disposal of shares to cover tax obligations, while common, slightly reduces the CFO's holdings.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, such as the CFO, when they engage in transactions involving the company's securities. It provides transparency to the market regarding insider activity.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies and their executives.
• The vesting schedule of the RSUs (25% annually over four years) is a common vesting structure in the pharmaceutical industry for executive compensation.
• Companies like Amgen, Biogen, and Gilead Sciences also have similar RSU vesting schedules for their executives.

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders.
• The disclosure provides transparency to shareholders regarding insider transactions.

Key Dates

Keywords

Kiniksa Pharmaceuticals, Mark Ragosa, CFO, Class A Ordinary Shares, Restricted Share Units, RSU, Form 4, SEC, Beneficial Ownership, Insider Trading